Skip to main content
. 2012 Jan 18;7(1):e28305. doi: 10.1371/journal.pone.0028305

Figure 4. mE3-mIg inhibits the development of primary tumor in CCR2−/− mice.

Figure 4

(A) Three groups of CCR2−/− and one of C57BL/6 mice were administered 7×106TRAMP C1-luc cells. 25 days later, mice were repeatedly administered (every 3 days) with 200 µg mE3-Ig, isotype-matched control mIgG or PBS and monitored for the development of the primary tumor. Results are shown as tumor volume ± SE. * Indicates p<0.001. (B) Imaging of the primary tumor was done on day 65, as recorded by the CCD camera(IVIS).Panels a, b & c show representative photos of a CCR2+/+ C57BL/6 mouse (a), CCR2−/− C57BL/6 mouse (b) and CCR2−/− mouse treated with mE3-mIg (c) which were i.p injected with 200 µl luciferin 5 min before the exposure . (C) Summery of the computerized CCCD analysis of six mice per group of control mice (WT), CCR2−/− mice and those treated with mE3-mIg. Results are shown as total flux (p/s ×104) ±SE. * Indicates p<0.001 when comparing b and c to a, ** Indicates p<0.001 p<0.005 c to b.